Veeva Systems Earnings Call Transcripts
Fiscal Year 2027
-
Q2 revenue and operating income exceeded guidance, driven by record commercial and CRM performance, strong AI momentum with Falcon, and continued growth in R&D and data products. Updated FY 2027 guidance reflects confidence in long-term growth, with new product adoption and strategic wins in top biopharma accounts.
-
Revenue and operating income exceeded guidance, driven by strong execution in AI, CRM, and Crossix. Ostro acquisition and Falcon AI platform signal continued innovation, while guidance remains conservative amid early-stage scaling of key R&D products.
Fiscal Year 2026
-
The discussion highlighted robust growth in commercial and R&D segments, accelerated AI innovation with Falcon and Vault AI, and evolving pricing models focused on business value. CRM migrations and Crossix performance remain strong, while Aspen CRM targets long-term horizontal expansion.
-
The event highlighted a strategic focus on building an industry cloud for life sciences, with AI integration (Vault AI and Falcon) driving efficiency and new revenue streams. CRM and data products are seeing strong adoption, and partnerships like IQVIA are unlocking new opportunities.
-
The meeting covered director elections and auditor ratification, with no additional proposals or shareholder questions. Voting was conducted online, and results will be filed publicly on Form 8-K.
-
Fiscal 2026 closed with revenue and operating income ahead of guidance, driven by strong R&D and Crossix growth, robust Vault CRM adoption, and expanding AI initiatives. FY 2027 guidance reflects continued momentum, with a focus on new product ramp, services, and long-term AI-driven efficiency.
-
Focused on building an integrated industry cloud for life sciences, the company is expanding its broad product portfolio, embedding AI across platforms, and maintaining strong growth and profitability. Key growth drivers include clinical, quality, and safety products, with a $6B revenue target by 2030.
-
Q3 results exceeded guidance with $811M revenue and strong performance across all segments. CRM now forms 20% of revenue, with growth in R&D, Crossix, and quality. Guidance was raised for Q4 and the year, supported by robust execution and innovation in AI and product offerings.
-
Q2 revenue and operating income exceeded guidance, with strong R&D and commercial performance. The IQVIA settlement removes key barriers, enabling new product integrations and future growth, while Veeva AI development advances with long-term market potential.
-
Q1 revenue and margins exceeded guidance, driven by strong Crossix and R&D performance. Vault CRM adoption accelerated, and Veeva AI is gaining traction with customers. Guidance remains cautious amid macro uncertainty, but no material impact has been seen yet.
Fiscal Year 2025
-
Strong Q3 results and broad execution are driving growth, especially in clinical, quality, and safety segments. AI integration is accelerating across products, with full rollout expected in 2026, and new partnerships and platform innovations are expanding market opportunities.
-
Management reaffirmed a $6 billion 2030 revenue goal, driven by organic growth, product innovation, and expanding AI integration. New markets and partnerships, such as with IQVIA, support a broad-based growth strategy, while a usage-based AI pricing model is set to launch.
-
Leadership highlighted ongoing transformation, with AI and new markets as key themes. CRM migration to Vault is driving innovation and customer wins, while Crossix and data businesses show strong growth. The IQVIA partnership reduces friction and supports broader integration, and long-term growth is supported by a diversified product suite.
-
The meeting covered the election of directors and ratification of KPMG as auditor, with no additional proposals or shareholder questions. Voting was conducted online, and results will be filed publicly.
-
A vertically focused life sciences software provider is targeting $6B in revenue by 2030, driven by resilient subscription products, innovation in analytics and data, and expansion into horizontal CRM. Strong profitability, disciplined capital allocation, and a mission-driven culture underpin its growth.
-
Cloud-based solutions for life sciences continue to drive strong growth, with a $6B revenue target by 2030. High market share, platform innovation, and expansion in data and AI position the company for sustained leadership and resilience amid industry shifts.
-
Q4 and FY25 results exceeded guidance, with $2.75B revenue and strong operating margins. Clinical and commercial segments saw major wins, new product launches, and robust AI innovation. FY26 guidance anticipates continued growth, with most top 20 CRM decisions expected by 2026.
-
The session highlighted robust growth targets, with R&D expected to drive two-thirds of revenue by 2030 and strong execution across a broad product portfolio. Product innovation, especially in AI and data-driven CRM, is a key differentiator, while disciplined investment and M&A strategies support long-term expansion.
-
Q3 FY2025 results exceeded guidance with $699M revenue and record 43.5% operating margin, driven by strong execution in Development Cloud and commercial segments. Vault CRM adoption accelerated, GenAI solutions launched, and customer trust deepened, supporting a stable outlook.
-
Q2 revenue and operating income exceeded guidance, driven by strong execution, product innovation, and robust adoption across CRM and R&D segments. Gross margins improved, guidance was raised, and new products like Service Center and Site Connect gained traction.
Fiscal Year 2024
-
Leadership highlighted strong execution, a robust innovation roadmap, and significant growth opportunities in both commercial and R&D segments. Integrated product suites, AI-driven features, and disciplined capital allocation underpin confidence in reaching $6 billion revenue by 2030.
-
A new 2030 revenue goal of $6 billion was set, doubling from 2025, driven by organic growth in life sciences and existing products. The company is entering horizontal enterprise markets with a measured, platform-first approach, while maintaining strong profitability and a values-driven operating model.
-
Life sciences continues to show strong R&D investment and positive long-term prospects, with Vault CRM and Compass data products gaining momentum. Unified clinical and R&D platforms offer significant growth potential, while transparent pricing and leadership changes support the vision of building an industry cloud for life sciences.
-
The meeting covered director elections, auditor ratification, a charter amendment, and executive compensation, with all proposals recommended for approval. No shareholder questions were received, and voting results will be filed publicly.
-
A unified industry cloud strategy is driving growth, with a $20B TAM and strong innovation in both R&D and commercial segments. AI and data integration are central to future opportunities, while new products and platform migrations are expanding customer value and market share.
-
An integrated industry cloud strategy is driving modernization and efficiency in life sciences, with a broad product suite, strong market position, and ongoing innovation in both software and data. Despite short-term macro challenges, long-term growth prospects remain robust, especially in clinical and data segments.